{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-07-29",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "status": "Terminated",
      "city": "Carlsbad",
      "state": "CA",
      "country": "United States",
      "classification": "Class I",
      "openfda": {},
      "product_type": "Drugs",
      "event_id": "90245",
      "recalling_firm": "Akcea Therapeutics, Inc.",
      "address_1": "2855 Gazelle Ct",
      "address_2": "",
      "postal_code": "92010-6670",
      "voluntary_mandated": "Voluntary: Firm initiated",
      "initial_firm_notification": "E-Mail",
      "distribution_pattern": "KY, USA",
      "recall_number": "D-1166-2022",
      "product_description": "Tegsedi (inotersen) Injection 284 mg/1.5 mL, Rx Only, Sterile solution for Subcutaneous Use, 4 prefilled syringes, each containing 284 mg of inotersen, (equivalent to 300 mg inotersen sodium in 1.5 ml of solution), Distributed by Sobi, Inc. Inc Waltham MA 02451, NDC: 72126-007-01",
      "product_quantity": "450 cartons",
      "reason_for_recall": "Superpotent: High Out of specification (OOS) test result for percent label claim (%LC).",
      "recall_initiation_date": "20220523",
      "center_classification_date": "20220627",
      "termination_date": "20230404",
      "report_date": "20220706",
      "code_info": "Lots: 028C21AB, 028C21AC, Exp. 05/2025",
      "more_code_info": ""
    }
  ]
}